Phase III Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy vs Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Locally Advanced or Metastatic Non Small-Cell Lung Cancer

-

Location(s): United States

Description

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC